MedTrace Logo

Study of Intracoronary CD34+ Cell Administration in Patients With Early Coronary Atherosclerosis

NCT03471611 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2022-02-07

No results posted yet for this study

Summary

How safe and effective are CD34+ cell intracoronary injections for treating coronary endothelial dysfunction (CED)?

Conditions

  • Atherosclerosis, Coronary

Interventions

DRUG

Autologous CD34+ Cells

The dose will be 1x10\^5 cells/kg, injected at the rate of 10 ml/min

DRUG

Granulocyte Colony-Stimulating Factor (G-CSF)

5mg/kg twice daily

Sponsors & Collaborators

Principal Investigators

  • Amir Lerman · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-15
Primary Completion
2020-10-02
Completion
2020-10-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03471611 on ClinicalTrials.gov